Avacta Group plc, a life sciences company focused on developing innovative oncology drugs and diagnostics, will be holding an online shareholder event on December 13th to review the Phase 1a data of its AVA6000 clinical trial. The event will be hosted on the Investor Meet Company platform and will feature presentations from Avacta's CEO, Chief Scientific Officer, and a consultant. Investors will have the opportunity to submit questions in advance for the Q&A session. The event will be live-streamed for investors who follow Avacta on the IMC platform, and those who do not have an account can sign up for free to receive an invitation.
Avacta's Therapeutics Division is focused on developing a pipeline of novel Affimer immunotherapies and pre|CISION tumour-targeted chemotherapies. The company aims to address the lack of durable response to current cancer immunotherapies and reduce the systemic toxicities caused by chemotherapies. Avacta's lead program, AVA6000, is a pre|CISION tumour-targeted form of the chemotherapy drug doxorubicin, which is currently in Phase 1 clinical trials for patients with locally advanced or metastatic solid tumors.
The Affimer platform developed by Avacta is an alternative to antibodies and aims to overcome the limitations of antibodies in the immuno-diagnostics and immuno-therapeutics markets. The pre|CISION tumour targeting platform allows for the selective release of active drugs in tumor tissue, reducing systemic exposure and minimizing damage to healthy tissues. This modification of chemotherapies aims to improve their safety and therapeutic potential in treating cancer.
Overall, Avacta's shareholder update will provide a detailed review of the AVA6000 Phase 1a data, offering investors insights into the progress of the clinical trial and the potential of Avacta's innovative oncology drugs and diagnostics.